AbbVie sues CMS over Botox Medicare price negotiation selection [developing]
Key Questions
Why is AbbVie suing CMS?
AbbVie filed a lawsuit against CMS on April 2, 2026, alleging overreach in selecting Botox for Medicare price negotiation. This challenges the pricing policy implications.
What was the FDA warning to the Texas medical spa?
The FDA issued a warning letter to a Texas medical spa for Botox dispensing discrepancies violating DSCSA regulations. It highlights compliance risks in Botox distribution.
What happened with AbbVie's collaboration with CollPlant?
CollPlant terminated its $26 million development deal with AbbVie's Allergan unit after a 60-day notice. The impact on AbbVie is described as negligible.
Lawsuit 2026-04-02 vs CMS overreach. FDA warns TX med spa DSCSA; TrenibotE Ph3 AAD safe/GLP-1 facial; biosim delay; CollPlant filler collab term negligible. Pricing risks tariffs/340B/TrumpRx.
Sources (2)
Updated Apr 13, 2026